Heike Wollmann
Research Subjects
Heike Wollmann has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Aakash Kumar
Institute of Medical Biology, Agency for Science Technology and Research (A*STAR), 8A Biomedical Grove, #06-06 Immunos, 138648, Singapore
1 shared publication- Ascia Eskin
Department of Human Genetics, and
1 shared publication Bernadette S. De Bakker
Department of Medical Biology, Section Clinical Anatomy and Embryology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
1 shared publication- Bruno Reversade
Laboratory of Human Genetics and Therapeutics, King Abdullah University of Science and Technology, Thuwal 23955, Kingdom of Saudi Arabia
1 shared publication Carine Bonnard
Institute of Medical Biology, Agency for Science Technology and Research (A*STAR), 8A Biomedical Grove, #06-06 Immunos, 138648, Singapore
1 shared publication- David Brough
Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, Northern Care Alliance NHS Foundation Trust, University of Manchester, Manchester, UK
1 shared publication
Latest Publications
- Open Access
- 4 November 2020
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 16 (11) , e1009084
Loss of hepatocyte cell division leads to liver inflammation and fibrosis
The liver possesses a remarkable regenerative capacity based partly on the ability of hepatocytes to re-enter the cell cycle and divide to replace damaged cells. This capability is substantially reduced upon chronic damage, but it is not clear if this is a cause or consequence of liver disease. Here, we investigate whether blocking hepatocyte division using two different mouse models affects physiology as well as clinical liver manifestations like fibrosis and inflammation. We find that in P14 Cdk1Liv-/- mice, where the division of hepatocytes is abolished, polyploidy, DNA damage, and increased p53 signaling are prevalent. Cdk1Liv-/- mice display classical markers of liver damage two weeks after birth, including elevated ALT, ALP, and bilirubin levels, despite the lack of exogenous liver injury. Inflammation was further studied using cytokine arrays, unveiling elevated levels of CCL2, TIMP1, CXCL10, and IL1-Rn in Cdk1Liv-/- liver, which resulted in increased numbers of monocytes. Ablation of CDK2-dependent DNA re-replication and polyploidy in Cdk1Liv-/- mice reversed most of these phenotypes. Overall, our data indicate that blocking hepatocyte division induces biological processes driving the onset of the disease phenotype. It suggests that the decrease in hepatocyte division observed in liver disease may not only be a consequence of fibrosis and inflammation, but also a pathological cue. “Pathological” polyploidy is a hallmark of liver diseases like NAFLD and NASH. Since loss of Cdk1 induces polyploidy, we used a mouse model with a hepatocyte-specific deletion of Cdk1 or Ccna2 to study the immediate effects on liver physiology. To our surprise, impaired hepatocyte proliferation results in the development of inflammation and fibrosis in young animals despite the lack of any treatment to promote liver damage. Furthermore, we show that this could be caused by polyploidy, as concurrent loss of Cdk2 reverses polyploidy and the inflammatory phenotype. Thus, we provide evidence that the loss of hepatocyte proliferation in liver disease is not only an outcome but could also be an etiology of liver pathology.
- 4 November 2020
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 16 (11) , e1009084
Open AccessLoss of hepatocyte cell division leads to liver inflammation and fibrosis
The liver possesses a remarkable regenerative capacity based partly on the ability of hepatocytes to re-enter the cell cycle and divide to replace damaged cells. This capability is substantially reduced upon chronic damage, but it is not clear if this is a cause or consequence of liver disease. Here, we investigate whether blocking hepatocyte division using two different mouse models affects physiology as well as clinical liver manifestations like fibrosis and inflammation. We find that in P14 Cdk1Liv-/- mice, where the division of hepatocytes is abolished, polyploidy, DNA damage, and increased p53 signaling are prevalent. Cdk1Liv-/- mice display classical markers of liver damage two weeks after birth, including elevated ALT, ALP, and bilirubin levels, despite the lack of exogenous liver injury. Inflammation was further studied using cytokine arrays, unveiling elevated levels of CCL2, TIMP1, CXCL10, and IL1-Rn in Cdk1Liv-/- liver, which resulted in increased numbers of monocytes. Ablation of CDK2-dependent DNA re-replication and polyploidy in Cdk1Liv-/- mice reversed most of these phenotypes. Overall, our data indicate that blocking hepatocyte division induces biological processes driving the onset of the disease phenotype. It suggests that the decrease in hepatocyte division observed in liver disease may not only be a consequence of fibrosis and inflammation, but also a pathological cue. “Pathological” polyploidy is a hallmark of liver diseases like NAFLD and NASH. Since loss of Cdk1 induces polyploidy, we used a mouse model with a hepatocyte-specific deletion of Cdk1 or Ccna2 to study the immediate effects on liver physiology. To our surprise, impaired hepatocyte proliferation results in the development of inflammation and fibrosis in young animals despite the lack of any treatment to promote liver damage. Furthermore, we show that this could be caused by polyploidy, as concurrent loss of Cdk2 reverses polyploidy and the inflammatory phenotype. Thus, we provide evidence that the loss of hepatocyte proliferation in liver disease is not only an outcome but could also be an etiology of liver pathology.
- Open Access
- 1 January 2020
- Published by The Company of Biologists in Development
- Vol. 147 (21)
Mitchell-Riley syndrome iPSC exhibit reduced pancreatic endoderm differentiation due to an RFX6 mutation
Mitchell-riley syndrome (MRS) is caused by recessive mutations in the Regulatory Factor X, 6 (RFX6) gene and is characterised by pancreatic hypoplasia and neonatal diabetes. To determine why MRS patients specifically lack pancreatic endocrine cells, we micro-CT imaged a 12-week old foetus homozygous for the nonsense mutation RFX6 c.1129C>T, which revealed loss of the pancreas body and tail. From this foetus, we derived iPSC and show that differentiation of these cells in vitro proceeds normally until generation of pancreatic endoderm, which is significantly reduced. We additionally generated an RFX6HA reporter allele by gene targeting in wild-type H9 cells to precisely define RFX6 expression and in parallel performed in situ hybridization for RFX6 in the dorsal pancreatic bud of a Carnegie Stage 14 human embryo. Both in vitro and in vivo, we find that RFX6 specifically labels a subset of PDX1-expressing pancreatic endoderm. In summary, RFX6 is essential for efficient differentiation of pancreatic endoderm, and its absence in MRS patients specifically impairs formation of endocrine cells of the pancreas head and tail.
- 1 January 2020
- Published by The Company of Biologists in Development
- Vol. 147 (21)
Open AccessMitchell-Riley syndrome iPSC exhibit reduced pancreatic endoderm differentiation due to an RFX6 mutation
Mitchell-riley syndrome (MRS) is caused by recessive mutations in the Regulatory Factor X, 6 (RFX6) gene and is characterised by pancreatic hypoplasia and neonatal diabetes. To determine why MRS patients specifically lack pancreatic endocrine cells, we micro-CT imaged a 12-week old foetus homozygous for the nonsense mutation RFX6 c.1129C>T, which revealed loss of the pancreas body and tail. From this foetus, we derived iPSC and show that differentiation of these cells in vitro proceeds normally until generation of pancreatic endoderm, which is significantly reduced. We additionally generated an RFX6HA reporter allele by gene targeting in wild-type H9 cells to precisely define RFX6 expression and in parallel performed in situ hybridization for RFX6 in the dorsal pancreatic bud of a Carnegie Stage 14 human embryo. Both in vitro and in vivo, we find that RFX6 specifically labels a subset of PDX1-expressing pancreatic endoderm. In summary, RFX6 is essential for efficient differentiation of pancreatic endoderm, and its absence in MRS patients specifically impairs formation of endocrine cells of the pancreas head and tail.